ORIGINAL CONTRIBUTION. Cognitive Impairment and the Brain Dopaminergic System in Parkinson Disease
|
|
- Joy Blair
- 5 years ago
- Views:
Transcription
1 ORIGINAL CONTRIBUTION Cognitive Impairment and the Brain Dopaminergic System in Parkinson Disease [ 18 F]Fluorodopa Positron Emission Tomographic Study Juha O. Rinne, MD, PhD; Raija Portin, PsychLic; Hanna Ruottinen, MD; Elina Nurmi, MD; Jörgen Bergman, MSc; Merja Haaparanta, MSc; Olof Solin, PhD Objective: To investigate the role of the brain dopaminergic system in cognitive impairment in patients with Parkinson disease (PD). Design: We studied 28 patients with PD and 16 agematched healthy control subjects using [ 18 F]fluorodopa (fluorodopa F 18) positron emission tomography. Patients with PD showed a variable degree of cognitive impairment, which was assessed using the Mini-Mental State Examination and detailed neuropsychologic assessment, including tests sensitive for frontal lobe function. Results: [ 18 F]Fluorodopa uptake was reduced in the putamen (to 36% of the control mean; P.001), the caudate nucleus (to 61% of the control mean; P.001), and the frontal cortex (to 45% of the control mean; P.001) in patients with PD compared with controls. There was no significant association between the degree of overall cognitive impairment of patients and [ 18 F]fluorodopa uptake values. The influx constant (K i ) in the caudate nucleus had a negative association with performance in the attention-demanding Stroop interference task, especially with the interference time. The K i in the frontal cortex had a positive correlation with performance in the digit span (backwards), verbal fluency, and verbal immediate recall tests. Thus, the better the patient performed in tasks demanding immediate and working memory and executive strategies, the better the [ 18 F]fluorodopa uptake in the frontal cortex. In the putamen, no significant correlation was seen between the K i value and any of the cognitive tests. The severity of the motor symptoms of PD and [ 18 F]fluorodopa uptake showed a negative correlation in the putamen (r = 0.38; P =.04), and in the caudate nucleus a similar trend was seen (r = 0.36; P =.06). Conclusions: Reduced [ 18 F]fluorodopa uptake in PD in the caudate nucleus (and frontal cortex) is related to impairment in neuropsychologic tests measuring verbal fluency, working memory, and attentional functioning reflecting frontal lobe function. This indicates that dysfunction of the dopamine system has an impact on the cognitive impairment of patients with PD. However, our results do not exclude the possibility of more generalized cognitive impairment in PD, the pathophysiology of which is probably different and more generalized. Arch Neurol. 2000;57: From the Department of Neurology, University of Turku (Drs Rinne, Portin, Ruottinen, and Nurmi), and the Turku PET Centre, Radiopharmaceutical Chemistry and Accelerator Laboratory, Åbo Akademi University (Mr Bergman, Ms Haaparanta, and Dr Solin), Turku, Finland. COGNITIVE IMPAIRMENT and dementia are common in Parkinson disease (PD). Patients have characteristic cognitive deficits, 1-3 and they show impairment especially in neuropsychologic tests thought to be sensitive for frontal lobe function. 1-5 Therefore, some investigators 4,6 have emphasized the frontal or frontostriatal nature of the cognitive deficits seen in PD, whereas others have suggested a more generalized profile of cognitive impairment 7 or have used a wider concept of subcortical dementia. 8 Thus, patients with PD might show specific, in particular frontal, and generalized cognitive dysfunctioning. The neuroanatomic basis of frontal deficits is suggested to be dysfunction of the neuronal loops connecting the basal ganglia and frontal lobes, 9 but the pathophysiological basis of these various types of cognitive deficits is still unclear. The majority of dopaminergic neurons are located in the substantia nigra (SN). The main projection from the SN is to the striatum (putamen and caudate nucleus). In addition, there are dopaminergic projections directly from the SN and ventral tegmental area to the cortical and limbic areas Thus, there are direct dopaminergic connections to the frontal brain areas. In addition, the caudate nucleus, receiving dopaminergic input from the SN, is connected to the frontal brain areas via neuronal loops. 9 Thus, by these connections, dopaminergic input to the caudate nucleus can indirectly affect frontal functions. Furthermore, increasing evidence suggests functional segregation of the pu- 470
2 SUBJECTS AND METHODS PATIENTS AND CONTROLS The study population consisted of 28 patients (17 women and 11 men) with idiopathic PD. Patients were diagnosed and regularly followed up at the Department of Neurology, University of Turku, Turku, Finland. All patients had a positive response to levodopa therapy. Mean patient age at the time of PET scanning was 64.1 years (range, years). The mean duration of disease was 14.5 years (range, years). The severity of the disease according to the modified Hoehn and Yahr scale 21 was 1.5 to 4.0 (mean, 2.7). The clinical characteristics of the patients are shown in Table 1. All patients were receiving levodopa. In addition, 14 patients were treated with a dopamine agonist, 9 of whom were also receiving selegiline hydrochloride. None of the patients were taking anticholinergic drugs at the time of neuropsychologic testing or the PET study. Control subjects (8 women and 8 men; age, mean [SD], 62.4 [6.6] years) were healthy volunteers without any history or signs of neurologic or psychiatric disease. There was no significant difference in demographic characteristics (sex distribution and age) between patients with PD and controls. To rule out any structural lesions, all subjects (patients and controls) underwent brain computed tomography (CT), magnetic resonance imaging (MRI), or both. All the scans were visually inspected and interpreted by an experienced neuroradiologist. All controls had normal findings, and 5 patients showed mild cortical atrophy including the frontal lobes. The study was approved by the joint ethical committee of University of Turku and University of Turku Hospital. All patients gave written informed consent. METHODS Neuropsychologic Assessment Overall cognitive performance was evaluated using the Mini-Mental State Examination 22 and the Mild Deterioration Battery (MDB 23,24 ) of verbal, visuomotor, and memory tests. The MDB was first used to determine the severity grades of cognitive impairment by comparing the overall performance of the patients with the age reference values derived from a sample of healthy individuals. Second, certain subtests of the MDB (digit span) and tests measuring verbal fluency and attention served as measures of cognitive functioning related to the frontal lobes. The MDB included 8 tests: 4 subtests of the Wechsler Adult Intelligence Scale 25 similarities (conceptual reasoning and semantic memory), digit span (immediate and working memory and attention), digit symbol (visuomotor speed), and block design (visuoconstructive skill) the Benton Revised Visual Retention Test, 26 immediate recall of 30 paired word associates (PWAs) for verbal memory, immediate recall of verbal-visual memory of 20 common objects, and naming time of 20 common objects. For overall evaluation, patients received deterioration points if their performance on any of the tests was below 1.5 SD compared with reference values obtained from healthy age-matched controls. 27,28 If the patient scored below 1.5 SD compared with the control group, he or she received 1 deterioration point; if below 2 SD, then 2 points; and if below 3 SD, then 3 points. Thus, the maximum deterioration score was 24. In addition, in the tasks of object memory and PWA, delayed recall after 1 hour was assessed to evaluate long-term memory function. More specific tests for frontal lobe function were conducted. First, 2 tasks on verbal fluency demanding executive strategies were studied. On the phonological fluency task, patients were asked to generate within 60 seconds as many words as possible beginning with the letter s. On the semantic fluency task, they were asked to name as many animals as possible within 60 seconds. Second, attentional functioning was measured using Stroop tasks with 4 colors. On the control task, patients were instructed to name the color of the ink of 100 rectangles as quickly as possible. On the interference task, patients named the color of the ink of 100 written words in which the color and the meaning were contradictory (eg, the word blue printed in red). This task requires continuous suppression of automatic processing of word meaning. A practice round preceded the interference task. The color naming times on the 2 tasks and the difference between them (interference time) served as variables in the Stroop test, 24,29 which was performed by 18 patients. The Beck Depression Inventory was also administered to all patients. 30 Positron Emission Tomography [ 18 F]Fluorodopa investigation was performed according to a protocol described previously by Ruottinen et al. 31 Positron emission tomographic investigations were performed using a scanner (Siemens/CTI 931/12/8; CTI, Knoxville, Tenn). This camera provides 15 transaxial planes, with an observed in-plane resolution of 8 mm after reconstruction. Patients were lying in the tomograph and positioned by an individual head holder with 3-dimensional laser beam alignment according to the orbitomeatal plane. The [ 18 F]fluorodopa synthesis was carried out according to the method of Namavari et al 32 and Bergman et al. 33 At the end of synthesis, the specific radioactivity was at least 44.4 MBq/µmol. The radiochemical purity exceeded 98% in every case. On average, a mean (SD) of (28.9) MBq of [ 18 F]fluorodopa was injected intravenously. A dynamic study with 37 time frames and a total duration of 90 minutes was performed. Regions of interest were drawn on the head of the caudate nucleus, putamen, medial frontal cortex, and lateral ipital cortex on 2 consecutive planes on integrated (20-90 minutes) PET images. The regions of interest were identified by visual inspection with the help of a neuroanatomic atlas and CT or MRI. The radioactivity concentrations were calculated for each region of interest, and the values of the corresponding anatomical structures on the 2 consecutive planes were averaged. The influx constant (K i ) was calculated with a multiple time graphical analysis approach, 34 modified using a nonspecific tissue (ipital cortex) rather than plasma input function, with a procedure previously described. 15,31,35 The K i reflects mainly decarboxylation of [ 18 F]fluorodopa to [ 18 F]fluorodopamine and the function of presynaptic dopaminergic terminals. Before statistical analysis, the K i values of the left and right structures were averaged. Continued on next page 471
3 STATISTICAL ANALYSIS The t test was used to compare [ 18 F]fluorodopa uptake between controls and patients with PD. The association between [ 18 F]fluorodopa uptake and cognitive test results was evaluated using a multiple linear analysis of regression. To adjust [ 18 F]fluorodopa uptake values for duration and severity of disease, the model we fitted was as follows: Response = b 0 +(b 1 Cognitive Test Result) +(b 2 Duration of Disease) +(b 3 Severity of Disease) + Error. tamen and caudate nucleus. The putamen might be more involved with motor behavior, whereas the caudate nucleus also participates in behavioral functions. 13 The main biochemical consequence of the progressive loss of nigrostriatal dopamine neurons in PD is a deficiency of dopamine in the striatum. When the dysfunction of the nigrostriatal dopamine system becomes more severe, the motor disability worsens Brain dopamine systems other than the nigrostriatal projections, such as those projecting directly to the cortical areas, are also affected in PD, as is indicated by a widespread reduction in dopamine content. 17 Patients with PD were impaired after withdrawal from levodopa therapy, especially in cognitive tests sensitive to frontal lobe function, 5,18,19 suggesting that dopamine is associated with frontal cognitive functions in PD. Some investigators, 20 however, have found levodopa therapy to be ineffective for cognitive symptoms. On the other hand, performance in tests measuring long-term memory, primarily reflecting medial temporal lobe functions, has been reported to improve in PD with dopaminergic therapy (for a review see Yanagisawa 20 ). Therefore, the dopamine system in different brain areas seems to be involved in many cognitive functions in PD, especially in those thought to be related to the function of the frontal lobes. The aim of this study was to investigate in vivo, using positron emission tomography (PET), whether the brain dopamine system is involved in cognitive functions in patients with PD. Our hypothesis was that there is an association between reduced [ 18 F]fluorodopa (fluorodopa F 18) uptake and defects in performance on cognitive tests sensitive to frontal lobe functions. RESULTS The mean (SD) Mini-Mental State Examination score of patients with PD was 26.0 (3.3) points (range, points), and the mean (SD) MDB score was 6.3 (6.2) (range, ). Six patients fulfilled clinical criteria (Diagnostic and Statistical Manual of Mental Disorders, Third Edition 36 ) for dementia, whereas 10 had only mild cognitive impairment. The remainder of the patients with PD (n = 12) were cognitively preserved. Mean [ 18 F]fluorodopa uptake values are presented in Table 2. There was a significant reduction in K i values in the putamen (to 36% of the control mean; P.001) Table 1. Clinical Characteristics of Patients With Parkinson Disease and Controls Characteristic Parkinson Disease Group (n = 28) Control Group (n = 16) Sex, F/M 17/11 8/8 Age, mean (SD), y 64.1 (6.9) 62.4 (6.6) Disease duration, mean (SD), y 14.5 (7.5)... Modified Hoehn and Yahr stage* *According to Fahn et al. 21 Table 2. [ 18 F]Fluorodopa Uptake Values in 28 Patients With Parkinson Disease and 16 Controls* K i, Mean (SD), min 1 Group Putamen Caudate Nucleus Frontal Cortex Parkinson disease 4.20 (1.73) 7.45 (2.42) 1.10 (0.65) Control (0.66) (0.89) 2.42 (0.85) *K i indicates influx constant. P.001. and the caudate nucleus (to 61% of the control mean; P.001) in patients with PD compared with controls. In the frontal cortex, K i values in patients with PD were reduced to 45% of the control mean (P.001). There was no significant association between the degree of overall cognitive impairment (Mini-Mental State Examination or MDB score) of the patients and the [ 18 F]fluorodopa uptake values. However, there was a trend toward reduced caudate K i values in patients with more severe overall cognitive impairment (MDB score vs K i : r = 0.35; P =.07). In addition, prolonged reaction time in the interference task (r = 0.51; P =.03) and prolonged interference time (r = 0.50; P =.03) in the attention-demanding Stroop test were related to reduced [ 18 F]fluorodopa uptake in the caudate nucleus. Similar association also was seen in the frontal cortex (Table 3). Moreover, there was a positive correlation between performance in the verbal fluency task (phonological fluency: r = 0.44; P =.04; semantic fluency: r = 0.44; P =.04) and [ 18 F]fluorodopa uptake in the frontal cortex. Performance in the verbal test of 30 PWAs for immediate recall was also better in patients with higher frontal [ 18 F]fluorodopa uptake (r = 0.39; P =.04). In contrast, performance on the Benton Revised Visual Retention Test and the delayed recall tasks of 30 PWAs and 20 objects did not have a significant correlation with [ 18 F]fluorodopa uptake in the caudate nucleus or the frontal cortex. Results of the regression analysis for correlations between K i values in different brain areas and results of cognitive tests after correcting for the effect of duration and severity of disease are shown in Table 3. In the Stroop test, there was a negative association between K i in the cau- 472
4 Table 3. Results of Multiple Regression Analysis of [ 18 F]Fluorodopa Uptake in 28 Patients With Parkinson Disease* Brain Area Caudate nucleus Test Regression Coefficient SE t P R 2,% Stroop Interference task, time Interference time Frontal cortex Digit span (backwards) Verbal fluency Phonological Semantic Paired word associates Immediate recall Stroop Interference task, time Interference time *Only explanatory variables that were significant in this analysis are shown. date nucleus and speed in the interference task. Furthermore, a similar trend was seen between caudate K i and the Stroop interference time. That is, the lower the K i in the caudate nucleus, the more time it took to perform the interference task compared with the control task. A similar trend between speed in the interference task and interference time in the Stroop test and K i was seen in the frontal cortex (Table 3). In addition, K i in the frontal cortex had a positive correlation with the performance in the digit span backwards, phonological fluency, and PWA immediate recall tests (Table 3). Thus, the better the patient performed on the tasks demanding immediate and working memory, the better the [ 18 F]fluorodopa uptake in the frontal cortex. In contrast, in the putamen, no significant correlation was seen between the K i value and any of the cognitive test results. The degree of depression, evaluated by the Beck Depression Inventory score, did not show any significant correlation with [ 18 F]fluorodopa uptake in any of the brain areas examined. As predictable, there was a significant negative correlation between the severity of the motor symptoms of PD and [ 18 F]fluorodopa uptake in the putamen (r = 0.38; P =.04). In the caudate nucleus, a similar trend was seen (r = 0.36; P =.06). COMMENT Our results show that dysfunction of the dopamine system in the caudate, but not in the putamen, is related to certain characteristics of cognitive impairment in PD. This association was seen only in neuropsychologic tests thought to be sensitive for frontal lobe function. Another factor emphasizing the selectivity of our findings is that no correlation between neuropsychologic test results reflecting temporal lobe function and [ 18 F]fluorodopa uptake was seen. Holthoff et al 37 studied 7 pairs of twins discordant for PD. They found a significant correlation between scores obtained in Buschke s selective reminding task and striatal [ 18 F]fluorodopa uptake. Both the twins with PD and their clinically asymptomatic cotwins were combined in a single group, which might have, at least partially, contributed to the high correlation found between the verbal memory test score and fluorodopa uptake (r = 0.8 and 0.9 for caudate and putamen, respectively). These verbal memory test scores comprised episodic memory, including delayed recall. These scores might focus on temporal rather than frontal lobe function. They found an association between performance in a selective reminding task and [ 18 F]fluorodopa uptake in the caudate nucleus and putamen. This might be explained to some extent by the combination of patients with PD and unaffected cotwins in a single group. In a subsequent study, Holthoff-Detto et al 38 found a correlation in patients with advanced PD (Hoehn and Yahr stage 2-4) between reduction in caudate uptake of [ 18 F]fluorodopa and impaired performance in delayed recall of the selective reminding task (a verbal task of episodic memory demanding medial temporal lobe function 39 ). In the putamen, no such correlation was seen. Our findings are in line with those of Holthoff-Detto et al 38 in that there was a correlation between some cognitive functions in PD and [ 18 F]fluorodopa uptake. However, our findings indicate that this association is seen not only in the caudate nucleus but also in the frontal cortex. Moreover, in our study, the significant association between [ 18 F]fluorodopa uptake and cognitive performance was seen in tests demanding working memory and attention, ie, in tests thought to be sensitive for frontal lobe functions. In contrast to previous results, 37,38 no significant association was seen for test variables primarily reflecting medial temporal lobe function, such as delayed recall performance. This does not exclude the possibility that there might be a relationship between temporal lobe dopamine function and performance in episodic memory tests in PD. In our study, the regions of interest were not placed using anatomical reference based on MRIs but were drawn directly on PET images. In the frontal cortex, the signalnoise ratio of [ 18 F]fluorodopa uptake is clearly lower than that in the striatum. Thus, there is a certain degree of uncertainty in the determination of [ 18 F]fluorodopa uptake in the frontal lobes. In addition, possible atrophy of the frontal lobes might be related to cognitive impairment of the patients. However, only 6 of our patients ful- 473
5 filled the clinical criteria for dementia, and only 1 showed mild frontal atrophy on CT or MRI indistinguishable from that seen in the rest of the patients. Altogether, only 5 patients had mild atrophy of the frontal lobes after visual inspection of the CT or MRI scans by an experienced neuroradiologist. However, our results concerning the frontal lobes should be interpreted as preliminary. Thus, in future studies on frontal cortex [ 18 F]fluorodopa uptake, it is important to coregister the PET scans with anatomical scans. In the striatum, [ 18 F]fluorodopa uptake reflects the function of presynaptic dopaminergic neurons. [ 18 F]Fluorodopa is converted by aromatic amino acid decarboxylase to [ 18 F]fluorodopamine, which is stored in vesicles in presynaptic terminals. However, the exact proportion of [ 18 F]fluorodopa uptake in the frontal cortex that is related to dopaminergic neurons cannot be estimated because amino acid decarboxylase is also present in the noradrenergic and serotoninergic neurons, and thus cortical [ 18 F]fluorodopa signal does not necessarily reflect solely the activity of dopaminergic cortical terminals. A correlation does not necessarily imply a causal relationship. An association between cognitive impairment and reduced [ 18 F]fluorodopa uptake might be due to an overall decline in dopaminergic function with increasing severity of disease. It might be accompanied also by cognitive impairment because it has been shown that in PD the probability of having cognitive impairment and the severity of this impairment increase with advanced disease, 27 although the duration of developing cognitive impairment might vary individually. However, in our statistical analyses, we took into consideration the duration and severity of the disease and still found an association between [ 18 F]fluorodopa uptake in the caudate nucleus and frontal cortex and cognitive performance of patients. More important, the correlations between [ 18 F]fluorodopa uptake and cognitive impairment were seen in the caudate nucleus (and frontal cortex), but in the putamen, which is thought to be related mainly to motor function, we did not see any significant correlations between [ 18 F]fluorodopa uptake and cognitive performance of patients. Pathological studies have shown a correlation between neuronal loss in those areas of the SN projecting to frontal areas and caudate nucleus and the degree of cognitive impairment of patients. 16,40 The neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) causes a selective dopaminergic lesion. In people exposed to MPTP, cognitive symptoms similar to those seen in PD were noted, ie, deficits in visuospatial and executive functions (such as the verbal fluency task). 41 Similar but less severe impairment was also found in asymptomatic (in the motor sense) persons with limited exposure to MPTP. 42 In addition, patients with PD show already at an early stage of the disease difficulties in performing tasks demanding executive functions (Wisconsin Card Sorting Test) and attentional functioning (Stroop test). 6,43 In this very early phase, the biochemical defect in PD is thought to be restricted to the dopaminergic system, at least in a subgroup of patients. These observations support the view that the brain dopaminergic system is involved with planning and internal control that is supposed to be under control of the frontal lobes. A key question is why dopaminergic therapy in the long run does not alleviate the cognitive impairment in PD as it does for the motor symptoms. There is evidence that especially those cognitive symptoms thought to be related to frontal lobe function improve with dopaminergic therapy, 5,18,20 whereas temporal lobe functions, for instance, do not change. 5,19 It is evident that dopaminergic defects alone cannot explain all the various cognitive symptoms and the possible development of dementia in PD. The pathophysiological basis of generalized cognitive impairment in PD might include concomitant Alzheimer pathologic features or the presence of cortical Lewy bodies and defects in neurotransmitter systems other than the dopaminergic system. This multifactorial basis of generalized cognitive impairment and dementia in PD involves various cortical areas and their connections. Therefore, ligands reflecting general metabolic activity such as [ 18 F]fluorodeoxyglucose understandably correlate with the degree of cognitive impairment in PD. 44,45 Frankly demented patients with PD show a pattern of reduced [ 18 F]fluorodeoxyglucose typically seen in Alzheimer disease, with posterior parietal and temporal areas being most affected. 46,47 This pattern is even described in one patient with PD showing at autopsy only Lewy body pathologic evidence and no Alzheimer-type lesions. 48 The severity of motor symptoms of our patients with PD correlated with reduced [ 18 F]fluorodopa uptake in the putamen, in accordance with pathological studies 16,39 showing preferentially ventrolateral loss of neurons in the SN correlating with the severity of motor symptoms of patients. Similar correlations have been found with PET or single photon emission CT studies using various dopaminergic ligands In our study in the caudate nucleus, the correlation between [ 18 F]fluorodopa uptake and motor performance was nonsignificant, although a trend for reduced [ 18 F]fluorodopa uptake with more severe motor symptoms was seen. One possible explanation for the modest correlation between motor symptoms and striatal [ 18 F]fluorodopa uptake is that in our patients the motor severity, assessed by the modified Hoehn and Yahr scale, was mainly 2, 2.5, or 3; only 1 patient was in stage 1.5 and 2 patients were in stage 4. In conclusion, our results show that reduced [ 18 F]fluorodopa uptake in the caudate nucleus and the frontal cortex is related to impairment in neuropsychologic tests for working memory, attentional, and executive functioning probably linked to frontal lobe function. This indicates that dysfunction of the dopamine system has an impact on cognitive impairment of patients with PD. However, our results do not exclude the possibility of more generalized cognitive impairment in PD, the pathophysiologic basis of which is probably also more generalized. Accepted for publication October 29, Financial support from the Turku University Foundation, Turku, Finland, and the Päivikki and Sakari Sohlberg Foundation, Helsinki, Finland, is gratefully acknowledged. 474
6 We thank the staff of the Turku PET Centre, Turku, Finland, for assistance in performing the positron emission tomographic investigations. Reprints: Juha O. Rinne, MD, PhD, Department of Neurology, University of Turku, FIN Turku, Finland ( REFERENCES 1. Robbins TW, James M, Owen AM, et al. Cognitive deficits in progressive supranuclear palsy, Parkinson s disease, and multiple system atrophy in tests sensitive to frontal lobe function. J Neurol Neurosurg Psychiatry. 1994;57: Pillon B, Dubois B, Lhermitte F, Agid Y. Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson s disease and Alzheimer s disease. Neurology. 1986;36: Pillon B, Deweer B, Agid Y, Dubois B. Explicit memory in Alzheimer s, Huntington s and Parkinson s disease. Arch Neurol. 1993;50: Taylor AE, Saint-Cyr JA, Lang AE. Frontal lobe dysfunction in Parkinson s disease: the cortical focus of neostriatal outflow. Brain. 1986;109: Lange KW, Paul GM, Robbins TW, Marsden CD. L-dopa and frontal cognitive function in Parkinson s disease. Adv Neurol. 1993;60: Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson s disease. Brain. 1983;106: Cooper JA, Sagar HJ, Jordan N, Harvey NS, Sullivan EV. Cognitive impairment in early, untreated Parkinson s disease and its relationship to motor disability. Brain. 1991;114: Cummings JL. Subcortical dementia: neuropsychology, neuropsychiatry and pathophysiology. Br J Psychiatry. 1986;149: Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci. 1986;9: Berger B, Gaspar P, Verney C. Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates. Trends Neurosci. 1991; 14: Gaspar P, Stepniewska I, Kaas JH. Topography and collateralization of the dopaminergic projections to motor and lateral prefrontal cortex in owl monkeys. J Comp Neurol. 1992;325: Gingrich JA, Caron M. Recent advances in the molecular biology of dopamine receptors. Ann Rev Neurosci. 1993;16: Bhatia KP, Marsden CD. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain. 1994;117: Bernheimer H, Birkmeyer W, Hornykiewicz O, et al. Brain dopamine and the syndrome of Parkinson and Huntington. J Neurol Sci. 1973;20: Brooks DJ, Salmon EP, Mathias CJ, et al. The relationship between locomotor disability, autonomic dysfunction and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson s disease, studied with PET. Ann Neurol. 1990;113: Rinne JO, Rummukainen J, Paljärvi L, Rinne UK. Dementia in Parkinson s disease is related to neuronal loss in the medial substantia nigra. Ann Neurol. 1989; 26: Scatton B, Javoy-Agid F, Rouquier F, et al. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson s disease. Brain Res. 1983;275: Gotham AM, Brown RG, Marsden CD. Frontal cognitive function in patients with Parkinson s disease on and off levodopa. Brain. 1988;111: Lange KW, Robbins TW, Marsden CD, James M, Owen AM, Paul GM. L-dopa withdrawal in Parkinson s disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology. 1992;107: Yanagisawa N. Historical review of research on functions of basal ganglia. Eur Neurol. 1996;36(suppl 1): Fahn S, Elton RL, members of the UPDRS Development Committee. Unified Parkinson s Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent Developments in Parkinson s Disease. Vol 2. Florham Park, NJ: Macmillan Healthcare Information; 1987: Folstein MF, Folstein SE, McHugh PR. Mini-Mental State : a practical method for grading the cognitive state of the patients for clinicians. J Psychiatr Res. 1975; 12: Kujala P, Portin R, Revonsuo A, Ruutiainen J. Automatic and controlled information processing in multiple sclerosis. Brain. 1994;117: Kujala P, Portin R, Revonsuo A, Ruutiainen J. Attention related performance in two cognitively different subgroups of patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 1995;59: Wechsler D. Manual for Wechsler Adult Intelligence Scale. New York, NY: Psychological Corp; Benton AL. The Revised Visual Retention Test. New York, NY: Psychological Corp; Portin R, Rinne UK. Neuropsychological responses of parkinsonian patients to long-term levodopa treatment. In: Rinne UK, Klinger M, Stamm G, eds. Parkinson s Disease: Current Progress, Problems and Management. Amsterdam, the Netherlands: Elsevier Biomedical Press; 1980: Revonsuo A, Portin R, Koivikko L, Rinne JO, Rinne UK. Slowing of information processing in Parkinson s disease. Brain Cogn. 1993;21: Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935; 18: Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh JK. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4: Ruottinen HM, Rinne JO, Haaparanta M, et al. [18F]Fluorodopa PET shows striatal dopaminergic dysfunction in juvenile neuronal ceroid lipofuscinosis. J Neurol Neurosurg Psychiatry. 1997;62: Namavari M, Bishop A, Satyamurthy N, Bida G, Barrio JR. Regioselective radiofluorodestannylation with [18F]F 2 and [18F]CH 3 COOF: a high yield synthesis of 6-[18F]fluoro-L-dopa. Appl Radiat Isot. 1992;43: Bergman J, Haaparanta M, Lehikoinen P, Solin O. Electrophilic synthesis of 6-[18F]fluoro-L-dopa, starting from aqueous [18F]fluorine. J Labelled Compounds Radiopharm. 1994;35: Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple time uptake data: generalizations. J Cereb Blood Flow Metab. 1985;5: Burn DJ, Mark MH, Playford ED, et al. Parkinson s disease in twins studied with [18F]dopa and positron emission tomography. Neurology. 1992;42: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition. Washington, DC: American Psychiatric Association; Holthoff VA, Vieregge P, Kessler J, et al. Discordant twins with Parkinson s disease: positron emission tomography and early signs of impaired cognitive circuits. Ann Neurol. 1994;36: Holthoff-Detto VA, Kessler J, Herholz K, et al. Functional effects of striatal dysfunction in Parkinson s disease. Arch Neurol. 1997;54: Squire LR, Zola-Morgan S. The medial temporal lobe memory system. Science. 1991;253: Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson s disease. J Neuropathol Exp Neurol. 1991;50: Stern Y, Langston JW. Intellectual changes in patients with MPTP-induced parkinsonism. Neurology. 1985;35: Stern Y, Tetrud JW, Martin WRW, Kutner SJ, Langston JW. Cognitive change following MPTP exposure. Neurology. 1990;40: Hietanen M, Teräväinen H. Cognitive performance in early Parkinson s disease. Acta Neurol Scand. 1986;37: Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic anatomy of Parkinson s disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord. 1990;5: Piert M, Koeppe RA, Giordani B, Minoshima S, Kuhl DE. Determination of regional rate constants from dynamic FDG-PET studies in Parkinson s disease. J Nucl Med. 1996;37: Karbe H, Holthoff V, Huber M, et al. Positron emission tomography in degenerative disorders of the dopaminergic system. J Neural Transm. 1992;4: Turjanski N, Brooks DJ. PET and the investigation of dementia in the parkinsonian patient. J Neural Transm. 1997;51(suppl): Schapiro MB, Crady C, Ball MJ, et al. Reductions in parietal/temporal cerebral glucose metabolism are not specific for Alzheimer s disease. Neurology. 1990; 40(suppl 1): Brucke T, Asenbaum S, Pozzera A, et al. Dopaminergic nerve cell loss in Parkinson s disease quantified with [I-123] -CIT and SPECT correlates with clinical findings. Mov Disord. 1994;9(suppl 1): Rinne JO, Kuikka JT, Bergström K, Rinne UK. Striatal dopamine transporter in different disability stages of Parkinson s disease studied with [123I] -CIT SPECT. Parkinsonism Related Disord. 1995;1: Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I] -CIT striatal uptake correlates with symptom severity in Parkinson s disease. Ann Neurol. 1995;38: Ishikawa T, Dhawan V, Kazumata K, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123- CIT-FP/SPECT and fluorine-18-fdopa/pet. J Nucl Med. 1996;37:
Usefulness of a dopamine transporter PET ligand [ 18 F]β-CFT in assessing disability in Parkinson s disease
J Neurol Neurosurg Psychiatry 1999;67:737 741 737 Department of Neurology, University of Turku; Turku PET Centre, Turku, Finland J O Rinne H Ruottinen Department of Radiology, P Sonninen Radiochemistry
More informationOriginal Articles. Calne, resting tremor. Mortimer, Pirozzolo, Hansch, & Webster, postural disturbance III
2004 97-106 Original Articles 1 2 3 1 1 2 3 47 22 III I II muscular rigidity postural disturbance resting tremor bradykinesia Calne, 2001 Mortimer, Pirozzolo, Hansch, & Webster, 1982 Tel: 02-23627076 E-mail:
More informationPET, especially with 6-18 F-fluoro-L-dopa ( 18 F-FDOPA)
Journal of Nuclear Medicine, published on May 14, 2009 as doi:10.2967/jnumed.108.061572 Simple Ratio Analysis of F-Fluorodopa Uptake in Striatal Subregions Separates Patients with Early Parkinson Disease
More informationShort communication. dwk&:key words: Parkinson s disease Single-photon emission tomography Dopamine transporter imaging Aging. Materials and methods
Short communication [ 123 I]β-CIT single-photon emission tomography in Parkinson s disease reveals a smaller decline in dopamine transporters with age than in controls G. Tissingh 1, P. Bergmans 1, J.
More informationFatigue in patients with Parkinson s disease
103 Fatigue in patients with Parkinson s disease Kazuo Abe, Mayako Takanashi and Takehiko Yanagihara Department of Neurology, Osaka University Graduate School of Medicine, Japan Purpose: Fatigue is a complaint
More informationVerbal and visual memory in patients with early Parkinson s disease: Effect of levodopa
Original Article Verbal and visual memory in patients with early Parkinson s disease: Effect of levodopa Sumit Singh, Madhuri Behari Department of Neurology, All India Institute of Medical Sciences, Ansari
More informationBasal ganglia motor circuit
Parkinson s Disease Basal ganglia motor circuit 1 Direct pathway (gas pedal) 2 Indirect pathway (brake) To release or augment the tonic inhibition of GPi on thalamus Direct pathway There is a tonic inhibition
More informationWorking memory in medicated patients with Parkinson's disease: the central executive seems to work
J7ournal of Neurology, Neurosurgery, and Psychiatry 1996;60:313-317 Working memory in medicated patients with Parkinson's disease: the central executive seems to work Nathalie Fournet, Olivier Moreaud,
More informationUpdate on functional brain imaging in Movement Disorders
Update on functional brain imaging in Movement Disorders Mario Masellis, MSc, MD, FRCPC, PhD Assistant Professor & Clinician-Scientist Sunnybrook Health Sciences Centre University of Toronto 53 rd CNSF
More informationAdaptational Approach to Cognitive Rehabilitation in Multiple Sclerosis: Description of Three Models of Care
Adaptational Approach to Cognitive Rehabilitation in Multiple Sclerosis: Description of Three Models of Care Päivi Hämäläinen, PhD; Arja Seinelä, MA; Juhani Ruutiainen, MD Masku Neurological Rehabilitation
More informationCitation for published version (APA): Portman, A. T. (2005). Parkinson's Disease: deep brain stimulation and FDOPA-PET Groningen: s.n.
University of Groningen Parkinson's Disease Portman, Axel Tiddo IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document
More informationCorrelation between motor and cognitive functions in the progressive course of Parkinson s disease
doi:10.1111/ncn3.53 ORIGINAL ARTICLE Correlation between motor and cognitive functions in the progressive course of Parkinson s disease Hidetomo Murakami,* Yoshiyuki Owan,* Yukiko Mori,* Kazuhisa Fujita,*
More informationGBME graduate course. Chapter 43. The Basal Ganglia
GBME graduate course Chapter 43. The Basal Ganglia Basal ganglia in history Parkinson s disease Huntington s disease Parkinson s disease 1817 Parkinson's disease (PD) is a degenerative disorder of the
More informationImaging biomarkers for Parkinson s disease
3 rd Congress of the European Academy of Neurology Amsterdam, The Netherlands, June 24 27, 2017 Teaching Course 6 MDS-ES/EAN: Neuroimaging in movement disorders - Level 2 Imaging biomarkers for Parkinson
More informationIntroduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge
Introduction, use of imaging and current guidelines John O Brien Professor of Old Age Psychiatry University of Cambridge Why do we undertake brain imaging in AD and other dementias? Exclude other causes
More informationresponsiveness HMPAO SPECT in Parkinson's disease before and after levodopa: correlation with dopaminergic (SSmTc HMPAO) as a tracer in 21 patients
18 1ournal of Neurology, Neurosurgery, and Psychiatry 1994;57:18-185 Department of Neurology H S Markus A J Lees Institute of Nuclear Medicine, University College and Middlesex School of Medicine, London,
More informationParkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817.
Parkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817. Four (4) hallmark clinical signs: 1) Tremor: (Note -
More informationComplementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson s disease
Brain (1997), 120, 2187 2195 Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson s disease Angelo Antonini, 1 Klaus L. Leenders,
More informationChronic Effects of Dopaminergic Replacement on Cognitive Function in Parkinson s Disease: A Two-Year Follow-Up Study of Previously Untreated Patients
Movement Disorders Vol. 15, No. 4, 2000, pp. 613 626 2000 Movement Disorder Society Chronic Effects of Dopaminergic Replacement on Cognitive Function in Parkinson s Disease: A Two-Year Follow-Up Study
More informationBrain imaging for the diagnosis of people with suspected dementia
Why do we undertake brain imaging in dementia? Brain imaging for the diagnosis of people with suspected dementia Not just because guidelines tell us to! Exclude other causes for dementia Help confirm diagnosis
More informationNature, prevalence and clinical significance. Barcelona, Spain
Nature, prevalence and clinical significance Jaime Kulisevsky Barcelona, Spain 1 Non motor (neuropsychiatric) symptoms are an integral part of Parkinson s s disease (PD) Affective disorders And are associated
More informationT he main symptoms of idiopathic Parkinson s disease
1211 PAPER How useful is [ 123 I]b-CIT SPECT in clinical practice? J Eerola, P J Tienari, S Kaakkola, P Nikkinen, J Launes... See end of article for authors affiliations... Correspondence to: Dr Johanna
More informationyears; baseline off-state Unified Parkinson s Disease Rating Scale (UPDRS) motor ratings 24.6 ± 6.8).
Jourdain et al. 1 Supplemental Data Supplemental Methods Subjects We studied 28 PD subjects (20 men and 8 women; age 61.0 ± 9.6 (mean ± SD) years; duration 8.7 ± 9.6 years; baseline off-state Unified Parkinson
More informationCOGNITIVE IMPAIRMENT IN PARKINSON S DISEASE
1 GENERAL INTRODUCTION GENERAL INTRODUCTION PARKINSON S DISEASE Parkinson s disease (PD) is a neurodegenerative movement disorder, named after James Parkinson who described some of its characteristic
More informationStatistical parametric mapping with 18 F-dopa PET shows bilaterally reduced striatal and nigral dopaminergic function in early Parkinson s disease
754 MRC Cyclotron Unit, Hammersmith Hospital, London, UK P K Morrish J S Rakshi T Uema D L Bailey D J Brooks Institute of Neurology, Queen Square, London, UK J Ashburner K J Friston D J Brooks Department
More informationDOWNLOAD PDF DOPAMINERGIC IMAGING IN PARKINSONS DISEASE : SPECT CHRISTOPH SCHERFLER AND WERNER POEWE
Chapter 1 : Imaging Approaches to Parkinson Disease The diagnosis of idiopathic Parkinson's disease (PD) can often be made on clinical grounds with a high degree of accuracy particularly in cases with
More informationConfusional state. Digit Span. Mini Mental State Examination MMSE. confusional state MRI
10 304 29 3 confusional state MRI 29 3 304 311 2009 Key Words memory test attention brain region causative disease subcortical dementia 1 Confusional state Digit Span 1 1 5 4 Mini Mental State Examination
More informationThe Frontal Lobes. Anatomy of the Frontal Lobes. Anatomy of the Frontal Lobes 3/2/2011. Portrait: Losing Frontal-Lobe Functions. Readings: KW Ch.
The Frontal Lobes Readings: KW Ch. 16 Portrait: Losing Frontal-Lobe Functions E.L. Highly organized college professor Became disorganized, showed little emotion, and began to miss deadlines Scores on intelligence
More informationUnderstanding L-dopa L and Metabolism in the Human Brain
Understanding L-dopa L Transport and Metabolism in the Human Brain Final Presentation for REU program August 3, 2006 Megan Mary Mekarski Advisor: Professor Linninger Dr. Libin Zhang Laboratory for Product
More informationPathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)
Pathogenesis of Degenerative Diseases and Dementias D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Dementias Defined: as the development of memory impairment and other cognitive deficits
More informationTranscranial sonography in movement disorders
Transcranial sonography in movement disorders Uwe Walter 1st Residential Training of the European Society of Neurosonology and Cerebral Hemodynamics September 7-12, 2008 Bertinoro, Italy Department of
More informationT he concept of vascular cognitive covers a
28 PAPER Cognitive profile of subcortical ischaemic vascular disease H Jokinen, H Kalska, R Mäntylä, T Pohjasvaara, R Ylikoski, M Hietanen, O Salonen, M Kaste, T Erkinjuntti... J Neurol Neurosurg Psychiatry
More informationParkinson's disease? Which factors predict cognitive decline in. dopaminergic lesions.
J7ournal ofneurology, Neurosurgery, and Psychiatry 1995;58:51-55 Department of Neurology, CHU Lille, France D Caparros-Lefebvre N Pecheux V Petit H Petit Department of Information Science, CHU Lille, France
More informationMaking Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease
Making Every Little Bit Count: Parkinson s Disease SHP Neurobiology of Development and Disease Parkinson s Disease Initially described symptomatically by Dr. James Parkinson in 1817 in An Essay on the
More informationCognitive-Motor Interference in Persons with Parkinson Disease
Cognitive-Motor Interference in Persons with Parkinson Disease Tara L. McIsaac, PhD, PT Associate Professor of Physical Therapy A.T. Still University Arizona School of Health Sciences October 11, 2014
More informationViews and Reviews. [ 123 I]FP-CIT (DaTscan) SPECT Brain Imaging in Patients with Suspected Parkinsonian Syndromes ABSTRACT
Views and Reviews [ 123 I]FP-CIT (DaTscan) SPECT Brain Imaging in Patients with Suspected Parkinsonian Syndromes Robert A. Hauser, MD, Donald G. Grosset, MD From the Departments of Neurology, Molecular
More informationT he prevalence of Parkinson s disease (PD) is nearly 1% in
708 PAPER Donepezil for cognitive impairment in Parkinson s disease: a randomised controlled study D Aarsland, K Laake, J P Larsen, C Janvin... See end of article for authors affiliations... Correspondence
More informationresult from non-dopaminergic lesions?
Journal of Neurology, Neurosurgery, and Psychiatry 1989;52:201-206 Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions? BERNARD PILLON, BRUNO DUBOIS, GIULIANA CUSIMANO,
More informationNEUROCOGNITIVE, OUTCOMES IN PKU: IT S TIME TO RAISE THE BAR
NEUROCOGNITIVE, OUTCOMES IN : IT S TIME TO RAISE THE BAR KEY POINTS 1. High Phenylalanine (Phe) levels harm the brain.. Traditional therapies do not completely protect individuals with. 3. New approaches
More informationDopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson s disease
Neuropsychologia 43 (2005) 823 832 Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson s disease Simon J.G. Lewis a,b,, Aleksandra Slabosz c,e, Trevor W. Robbins
More informationNeurodegenerative Disease. April 12, Cunningham. Department of Neurosciences
Neurodegenerative Disease April 12, 2017 Cunningham Department of Neurosciences NEURODEGENERATIVE DISEASE Any of a group of hereditary and sporadic conditions characterized by progressive dysfunction,
More informationCognitive and Behavioural Changes After Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson s Disease
17 Cognitive and Behavioural Changes After Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson s Disease Antonio Daniele, Pietro Spinelli and Chiara Piccininni Istituto di Neurologia, Università
More informationStructural Changes of the Substantia Nigra in Parkinson s Disease as Revealed by MR Imaging
AJNR Am J Neuroradiol 21:697 701, April 2000 Structural Changes of the Substantia Nigra in Parkinson s Disease as Revealed by MR Imaging Michael Hutchinson and Ulrich Raff BACKGROUND AND PURPOSE: The possibility
More informationDementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada
Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends
More informationUniversity of Zagreb Medical School Repository
Središnja medicinska knjižnica Relja, M., Klepac, N. (2006) A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease. Journal of the Neurological Sciences, 248 (1-2). pp. 251-254.
More informationPET evaluation of the relationship between D 2 receptor binding and glucose metabolism in patients with parkinsonism
ORIGINAL ARTICLE Annals of Nuclear Medicine Vol. 19, No. 4, 267 275, 2005 PET evaluation of the relationship between D 2 receptor binding and glucose metabolism in patients with parkinsonism Makoto NAKAGAWA,*
More informationBehavioural Correlates of Cognitive Skill Learning in Parkinson s Disease
The Open Behavioral Science Journal, 2008, 2, 1-12 1 Behavioural Correlates of Cognitive Skill Learning in Parkinson s Disease M.H. Beauchamp 1, A. Dagher 2, M. Panisset 2,3 and J. Doyon *,1,2,4 1 Université
More informationNeuropsychological pattern of striatonigral
174 17ournal of Neurology, Neurosurgery, and Psychiatry 1 995;58: 174-179 INSERM U 289 and Federation de Neurologie, Hopital de la Salpetriere, 47 Boulevard de l'hopital, 75651 Paris cedex 13, France B
More informationClinical Features and Treatment of Parkinson s Disease
Clinical Features and Treatment of Parkinson s Disease Richard Camicioli, MD, FRCPC Cognitive and Movement Disorders Department of Medicine University of Alberta 1 Objectives To review the diagnosis and
More informationAnatomy of the basal ganglia. Dana Cohen Gonda Brain Research Center, room 410
Anatomy of the basal ganglia Dana Cohen Gonda Brain Research Center, room 410 danacoh@gmail.com The basal ganglia The nuclei form a small minority of the brain s neuronal population. Little is known about
More information212 Index C-SB-13,
Index A Acetylcholinesterase inhibitor, treatment, 15 Age-associated memory impairment (AAMI), 5 Alzheimer s disease (AD), 40, 95 96 apolipoprotein E genotype and risk for, 58 cellular neurodegeneration
More informationThe Nervous System. Neuron 01/12/2011. The Synapse: The Processor
The Nervous System Neuron Nucleus Cell body Dendrites they are part of the cell body of a neuron that collect chemical and electrical signals from other neurons at synapses and convert them into electrical
More informationIl ruolo di nuove tecniche di imaging per la diagnosi precoce di demenza
Parma, 23 maggio 2017 Il ruolo di nuove tecniche di imaging per la diagnosi precoce di demenza Livia Ruffini SC Medicina Nucleare Azienda Ospedaliero-Universitaria di Parma PET AND SPECT STUDIES OF THE
More informationCOGNITIVE SCIENCE 17. Peeking Inside The Head. Part 1. Jaime A. Pineda, Ph.D.
COGNITIVE SCIENCE 17 Peeking Inside The Head Part 1 Jaime A. Pineda, Ph.D. Imaging The Living Brain! Computed Tomography (CT)! Magnetic Resonance Imaging (MRI)! Positron Emission Tomography (PET)! Functional
More informationNon Alzheimer Dementias
Non Alzheimer Dementias Randolph B Schiffer Department of Neuropsychiatry and Behavioral Science Texas Tech University Health Sciences Center 9/11/2007 Statement of Financial Disclosure Randolph B Schiffer,,
More informationNeuropsychiatric Symptoms of Patients With Progressive Supranuclear Palsy and Parkinson s Disease
Neuropsychiatric Symptoms of Patients With Progressive Supranuclear Palsy and Parkinson s Disease Dag Aarsland, M.D., Ph.D. Irene Litvan, M.D. Jan P. Larsen, M.D., Ph.D. Neuropsychiatric symptoms are common
More informationExtrapyramidal Motor System. Basal Ganglia or Striatum. Basal Ganglia or Striatum 3/3/2010
Extrapyramidal Motor System Basal Ganglia or Striatum Descending extrapyramidal paths receive input from other parts of motor system: From the cerebellum From the basal ganglia or corpus striatum Caudate
More informationMaking Things Happen 2: Motor Disorders
Making Things Happen 2: Motor Disorders How Your Brain Works Prof. Jan Schnupp wschnupp@cityu.edu.hk HowYourBrainWorks.net On the Menu in This Lecture In the previous lecture we saw how motor cortex and
More informationFDG-PET e parkinsonismi
Parkinsonismi FDG-PET e parkinsonismi Valentina Berti Dipartimento di Scienze Biomediche, Sperimentali e Cliniche Sez. Medicina Nucleare Università degli Studi di Firenze History 140 PubMed: FDG AND parkinsonism
More informationBehavioural Brain Research
Behavioural Brain Research 199 (2009) 53 60 Contents lists available at ScienceDirect Behavioural Brain Research journal homepage: www.elsevier.com/locate/bbr Review The role of the basal ganglia in learning
More informationWorking Memory Functioning in Medicated Parkinson's Disease Patients and the Effect of Withdrawal of Dopaminergic Medication
Neuropsychology Copyright 2000 by the American Psychological Association, Inc. 2000, Vol. 14, No. 2, 247-253 0894-4105/00/$5.00 DOI: 10.1037//0894-4105.14.2.247 Working Memory Functioning in Medicated
More informationHallucinations and conscious access to visual inputs in Parkinson s disease
Supplemental informations Hallucinations and conscious access to visual inputs in Parkinson s disease Stéphanie Lefebvre, PhD^1,2, Guillaume Baille, MD^4, Renaud Jardri MD, PhD 1,2 Lucie Plomhause, PhD
More informationClinimetrics, clinical profile and prognosis in early Parkinson s disease Post, B.
UvA-DARE (Digital Academic Repository) Clinimetrics, clinical profile and prognosis in early Parkinson s disease Post, B. Link to publication Citation for published version (APA): Post, B. (2009). Clinimetrics,
More informationPET ligands and metabolic brain imaging Prof. Karl Herholz
PET ligands Karl Herholz, University of Manchester PET images in this lecture, unless indicated otherwise, are from Max-Planck-Institute for Neurological Research, Cologne, Germany 1 Positron-Emission-Tomography
More informationSPECT Dopamin Transporter lmaging Agent
SPECT Dopamin Transporter lmaging Agent Product Summary Product Name DATrace-123 Injection Active Ingredient Action Mechanism DATrace-123 is used as a radiopharmaceutical for the SPECT imaging of Dopamine
More informationSubject Index. Band of Giacomini 22 Benton Visual Retention Test 66 68
Subject Index Adams, R.D. 4 Addenbrooke s Cognitive Examination 101 Alzheimer s disease clinical assessment histological imaging 104 neuroimaging 101 104 neuropsychological assessment 101 clinical presentation
More informationREVIEW. KEY WORDS Dopamine, Parkinson s disease, Frontal cortex, Striatum, Functional neuroimaging
Cognitive Dysfunction in Parkinson s Disease: The Role of Frontostriatal Circuitry ADRIAN M. OWEN Medical Research Council Cognition and Brain Sciences REVIEW It has been known for many years that the
More informationCorporate Medical Policy
Corporate Medical Policy Dopamine Transporter Imaging with Single Photon Emission File Name: Origination: Last CAP Review: Next CAP Review: Last Review: dopamine_transporter_imaging_with_single_photon_emission_computed_tomography
More informationRound table: Moderator; Fereshteh Sedaghat, MD, PhD Brain Mapping in Dementias and Non-invasive Neurostimulation
Round table: Moderator; Fereshteh Sedaghat, MD, PhD Brain Mapping in Dementias and Non-invasive Neurostimulation 1. Reflection of Mild Cognitive Impairment (MCI) and Dementias by Molecular Imaging, PET
More informationTeach-SHEET Basal Ganglia
Teach-SHEET Basal Ganglia Purves D, et al. Neuroscience, 5 th Ed., Sinauer Associates, 2012 Common organizational principles Basic Circuits or Loops: Motor loop concerned with learned movements (scaling
More informationNEUROIMAGING IN PANS/PANDAS
NEUROIMAGING IN PANS/PANDAS Harry T. Chugani, M.D. Chief, Pediatric Neurology Nemours A.I. dupont Hospital for Children Wilmington, Delaware, USA Professor of Pediatrics and Neurology Thomas Jefferson
More informationTwo multidisciplinary teams of investigators have
Dopamine Cell Implantation in Parkinson s Disease: Long-Term Clinical and F-FDOPA PET Outcomes Yilong Ma 1,2, Chengke Tang 1, Thomas Chaly 1,2, Paul Greene 3, Robert Breeze 4, Stanley Fahn 3, Curt Freed
More informationD eep brain stimulation of the subthalamic nucleus (STN
PAPER Disease progression continues in patients with advanced Parkinson s disease and effective subthalamic nucleus stimulation R Hilker*, A T Portman*, J Voges, M J Staal, L Burghaus, T van Laar, A Koulousakis,
More informationErin Cullnan Research Assistant, University of Illinois at Chicago
Dr. Moises Gaviria Distinguished Professor of Psychiatry, University of Illinois at Chicago Director of Consultation Liaison Service, Advocate Christ Medical Center Director of the Older Adult Program,
More informationModulation of the Neural Circuitry Underlying Obsessive-Compulsive Disorder
BRAIN STIMULATION LABORATORY Modulation of the Neural Circuitry Underlying Obsessive-Compulsive Disorder OCD Awareness Day NOLAN WILLIAMS, M.D. Instructor Department of Psychiatry Stanford University October
More informationFDOPA, C11Choline, C11 Methionine. Dr K.G.Kallur
FDOPA, C11Choline, C11 Methionine Dr K.G.Kallur Why? 11C Methionine scan Had undergone resection Earlier. Post op recurrent hypercalcemia C11 Methionine Unable to see in Sestamibi scan Brain Tumor After
More informationFluorodeoxyglucose Positron Emission Tomography in Richardson s Syndrome and Progressive Supranuclear Palsy-Parkinsonism
BRIEF REPORT Fluorodeoxyglucose Positron Emission Tomography in Richardson s Syndrome and Progressive Supranuclear Palsy-Parkinsonism Karin Srulijes, MD, 1,2 Matthias Reimold, MD, 3 Rajka M. Liscic, MD,
More informationCASE 49. What type of memory is available for conscious retrieval? Which part of the brain stores semantic (factual) memories?
CASE 49 A 43-year-old woman is brought to her primary care physician by her family because of concerns about her forgetfulness. The patient has a history of Down syndrome but no other medical problems.
More informationBasal Ganglia. Steven McLoon Department of Neuroscience University of Minnesota
Basal Ganglia Steven McLoon Department of Neuroscience University of Minnesota 1 Course News Graduate School Discussion Wednesday, Nov 1, 11:00am MoosT 2-690 with Paul Mermelstein (invite your friends)
More informationDamage on one side.. (Notes) Just remember: Unilateral damage to basal ganglia causes contralateral symptoms.
Lecture 20 - Basal Ganglia Basal Ganglia (Nolte 5 th Ed pp 464) Damage to the basal ganglia produces involuntary movements. Although the basal ganglia do not influence LMN directly (to cause this involuntary
More informationDND. 18F-FP-CIT Positron Emission Tomography for Correlating Motor and Cognitive Symptoms of Parkinson s Disease INTRODUCTION
Print ISSN 1738-1495 / On-line ISSN 2384-0757 Dement Neurocogn Disord 2017;16(3):57-63 / https://doi.org/10.12779/dnd.2017.16.3.57 ORIGINAL ARTICLE 18F-FP-CIT Positron Emission Tomography for Correlating
More informationSupplementary Online Content
Supplementary Online Content Jauhar S, Nour MM, Veronese M, et al. A test of the transdiagnostic dopamine hypothesis of psychosis using positron emission tomographic imaging in bipolar affective disorder
More informationFunctional Role of the Basal Ganglia in the Planning and Execution of Actions
Functional Role of the Basal Ganglia in the Planning and Execution of Actions Oury Monchi, PhD, 1,2 Michael Petrides, PhD, 3 Antonio P. Strafella, MD, PhD, 3 Keith J. Worsley, PhD, 3 and Julien Doyon,
More informationNeuroimaging for dementia diagnosis. Guidance from the London Dementia Clinical Network
Neuroimaging for dementia diagnosis Guidance from the London Dementia Clinical Network Authors Dr Stephen Orleans-Foli Consultant Psychiatrist, West London Mental Health NHS Trust Dr Jeremy Isaacs Consultant
More informationCognitive Impairment and Magnetic Resonance Changes in Multiple Sclerosis. Background
Cognitive Impairment and Magnetic Resonance Changes in Multiple Sclerosis Victoria A Levasseur 1,2, Samantha Lancia 1, Gautam Adusumilli 1, Zach Goodman 1, Stuart D. Cook 3, Diego Cadavid 4, Robert T.
More informationAssociation Between Decline in Brain Dopamine Activity With Age and Cognitive and Motor Impairment in Healthy Individuals
VOLKOW, DECLINE Am J Psychiatry IN GUR, BRAIN WANG, 155:3, DOPAMINE March ET AL. 1998 ACTIVITY WITH AGE Association Between Decline in Brain Dopamine Activity With Age and Cognitive and Motor Impairment
More informationOutline. Biological Psychology: Research Methods. Dr. Katherine Mickley Steinmetz
Biological Psychology: Research Methods Dr. Katherine Mickley Steinmetz Outline Neuroscience Methods Histology Electrophysiological Recordings Lesion Neuroimaging Neuroanatomy Histology: Brain structure
More informationCEREBRAL BLOOD FLOW AND METABOLISM
Supported by: HURO/0901/069/2.3.1 HU-RO-DOCS CEREBRAL BLOOD FLOW AND METABOLISM Part 3 Modern imaging methods SPECT, PET, nmri History of Nuclear Medicine Starts with the invention of the X-ray 1946: radioactive
More informationStudy of Verbal Working Memory in Patients with Parkinson s Disease
Study of Verbal Working Memory in Patients with Parkinson s Disease Gilbert, Belleville, Bherer, & Chouinard, 2005 presented by Jonathan Reinharth May 2, 2005 Parkinson s Disease Symptoms: resting tremors,
More informationCSE511 Brain & Memory Modeling Lect 22,24,25: Memory Systems
CSE511 Brain & Memory Modeling Lect 22,24,25: Memory Systems Compare Chap 31 of Purves et al., 5e Chap 24 of Bear et al., 3e Larry Wittie Computer Science, StonyBrook University http://www.cs.sunysb.edu/~cse511
More informationMorphological and functional imaging studies on the diagnosis and progression of Parkinson s disease
J Neurol (2000) 247 [Suppl 2] : II/11 II/ Steinkopff Verlag 2000 David J. Brooks Morphological and functional imaging studies on the diagnosis and progression of Parkinson s disease D. J. Brooks ( ) MRC
More informationRange of neuropsychiatric disturbances in patients with Parkinson s disease
492 Section of Geriatric Psychiatry, Rogaland Psychiatric Hospital D Aarsland N G Lim C Janvin Department of Neurology, Central Hospital of Rogaland, Stavanger, Norway J P Larsen K Karlsen E Tandberg Departments
More informationthen a mechanism of reduced conversion and storage of administered levodopa as a cause for declining
Journal ofneurology, Neurosurgery, and Psychiatry 1989;52:72-76 Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations.
More informationNeuropsychological Evaluation of
Neuropsychological Evaluation of Alzheimer s Disease Joanne M. Hamilton, Ph.D. Shiley-Marcos Alzheimer s Disease Research Center Department of Neurosciences University of California, San Diego Establish
More informationDIFFERENTIAL DIAGNOSIS SARAH MARRINAN
Parkinson s Academy Registrar Masterclass Sheffield DIFFERENTIAL DIAGNOSIS SARAH MARRINAN 17 th September 2014 Objectives Importance of age in diagnosis Diagnostic challenges Brain Bank criteria Differential
More informationCognitive deficits in progressive supranuclear
J7ournal of Neurology, Neurosurgery, and Psychiatry 1994;57:79-88 ognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe
More informationNeuropsychiatric features of corticobasal degeneration
J Neurol Neurosurg Psychiatry 1998;65:717 721 717 Neuropharmacology Unit, Defense and Veteran Head Injury Program, Jackson Foundation and the Medical Neurology Branch I Litvan National Institutes of Neurological
More informationStrick Lecture 4 March 29, 2006 Page 1
Strick Lecture 4 March 29, 2006 Page 1 Basal Ganglia OUTLINE- I. Structures included in the basal ganglia II. III. IV. Skeleton diagram of Basal Ganglia Loops with cortex Similarity with Cerebellar Loops
More informationKEY SUMMARY. Mirapexin /Sifrol (pramipexole): What it is and how it works. What is Mirapexin /Sifrol (pramipexole)?
KEY SUMMARY 1. Mirapexin /Sifrol (pramipexole*) is a selective non-ergot dopamine agonist approved as immediate release since 1997 for the treatment of the signs and symptoms of idiopathic Parkinson's
More information